ReviewHuman vaccines & immunotherapeutics2017
Q-vaxcelerate: A distributed development approach for a new Coxiella burnetii vaccine.
Review in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Control of human Q fever by vaccination: the journey to Q-VAX and beyond.Infection and immunity · 2025Review
- Overview of the Q fever vaccine development: current status and future prospects.Antonie van Leeuwenhoek · 2025Review
- Efficacy of Phase I and Phase IIVaccines · 2023Article
- Genome-wide epitope mapping across multiple host species reveals significant diversity in antibody responses toFrontiers in immunology · 2023Article
- A global overview of the most important zoonotic bacteria pathogens transmitted fromInfectious medicine · 2022Review
- Spinning sugars in antigen biosynthesis: characterization of the Coxiella burnetii and Streptomyces griseus TDP-sugar epimerases.The Journal of biological chemistry · 2022Article
- Challenges and Opportunities in the Use of High and Maximum Biocontainment Facilities in Developing and Licensing Risk Group 3 and Risk Group 4 Agent Veterinary Vaccines.ILAR journal · 2022Article
- Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models ofFrontiers in immunology · 2022Article
- Contributions of lipopolysaccharide and the type IVB secretion system to Coxiella burnetii vaccine efficacy and reactogenicity.NPJ vaccines · 2021Article
- Recent Advances on the Innate Immune Response toFrontiers in cellular and infection microbiology · 2021Review
- Coxiella burnetii: international pathogen of mystery.Microbes and infection · 2020Review
- Coxiella burnetii Epitope-Specific T-Cell Responses in Patients with Chronic Q Fever.Infection and immunity · 2019Article
- PromiscuousFrontiers in immunology · 2019Article
- Article
- Zoonoses under our noses.Microbes and infectionReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of vaccines that are both safe and effective remains a costly and time-consuming challenge. To accelerate the pace of development and improve the efficacy and safety of candidate vaccines for both existing and emerging infectious agents, we have used a distributed development approach. This features the managed integration of individual expert groups having the requisite vaccine platforms, pre-clinical models, assays, skills and knowledge pertinent to a specific pathogen into a single, end-to-end development team capable of producing a new vaccine tailored to that particular agent. Distributed development focuses on integrating existing effort across multiple institutions rather than developing new capabilities or consolidating resources within an individual organization. Previously we have used the distributed development strategy to generate vaccine candidates for emerging viral diseases. Coxiella burnetii is a highly infectious and resilient bacterium and the causative agent of Q fever. Treatment for Q fever can require months of antibiotics. The current vaccine for Q-fever is only approved in Australia and requires prescreening due to the potential for severe reactogenicity in previously exposed individuals. Here we discuss Q-VaxCelerate, a distributed development consortium for the development of a new vaccine to prevent Q fever.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.